scout
News|Videos|January 30, 2024

Nivolumab Plus Ipilimumab Versus Sunitinib For First-Line Treatment of Advanced Renal Cell Carcinoma: Long-Term Follow-Up Data From the Phase 3 CheckMate 214 Trial

Nizar Tannir, MD, FACP, presents extended follow-up data assessing the combination of nivolumab and ipilimumab compared with sunitinib in the frontline setting of patients with advanced renal cell carcinoma (RCC).

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME